Skip to main
AVXL

AVXL Stock Forecast & Price Target

AVXL Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Anavex Life Sciences is conducting pre-clinical and clinical research in order to develop precision medicine treatments for neurodegenerative and neurodevelopmental diseases, including Alzheimer's, Parkinson's and Rett syndrome, which have a high unmet need. The company's strategic decision to withdraw its application with the EMA while continuing to engage with FDA shows disciplined management and preserves optionality for future interactions. With supportive data on the correlation between brain-volume preservation and endpoint movement, as well as long-term open-label data demonstrating the potential for time saved, the company's precision-medicine narrative continues to gain strength.

Bears say

Anavex Life Sciences is in a precarious position, with potential challenges in both the EU and U.S. markets. While the company has shown determination in seeking regulatory approval, the lack of a clear path forward presents potential risks to their success. Additionally, with ongoing development in other indications, the company must prove the viability of its pipeline.

AVXL has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Anavex Life Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Anavex Life Sciences (AVXL) Forecast

Analysts have given AVXL a Strong Buy based on their latest research and market trends.

According to 2 analysts, AVXL has a Strong Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Anavex Life Sciences (AVXL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.